Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
- PMID: 19636022
- DOI: 10.1200/JCO.2008.18.8193
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
Abstract
Purpose: Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit. This phase I dose escalation study was conducted to evaluate the safety and tolerability of telatinib, with additional pharmacokinetic, pharmacodynamic, and efficacy assessments.
Patients and methods: Patients with solid tumors refractory to standard therapies or with no standard therapy available were enrolled. Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily.
Results: Fifty-three patients were enrolled. Most frequently observed drug-related adverse events were nausea (26.4%; grade >or= 3, 0%) and hypertension (20.8%; grade 3, 11.3%; grade 4, 0%). Two dose-limiting toxicities were observed: one poorly controlled hypertension (600 mg twice daily), and one grade 2 weight loss, anorexia, and fatigue (1,500 mg twice daily). A formal maximum-tolerated dose was not reached. Telatinib was rapidly absorbed, with median time to peak concentration (t(max)) lower than 3 hours after dose. A nearly dose-proportional increase in exposure was observed with substantial variability. Telatinib half-life averaged 5.5 hours. Biomarker analyses showed dose-dependent increase in VEGF levels and decrease in plasma soluble VEGFR-2 levels, with a plateau at 900 mg twice daily. A decrease in tumor blood flow (K(trans) and IAUC(60)) was observed with dynamic contrast-enhanced magnetic resonance imaging. Best tumor response was stable disease, observed in 50.9% of patients.
Conclusion: Telatinib was safe and well tolerated up to 1,500 mg twice daily. Based on pharmacodynamic and pharmacokinetic end points, telatinib 900 mg twice daily is the recommended dose for subsequent phase II studies.
Similar articles
-
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.J Clin Oncol. 2005 Jun 20;23(18):4162-71. doi: 10.1200/JCO.2005.09.034. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867205 Clinical Trial.
-
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. Clin Cancer Res. 2010. PMID: 20233884 Clinical Trial.
-
Phase I trial of pazopanib in patients with advanced cancer.Clin Cancer Res. 2009 Jun 15;15(12):4220-7. doi: 10.1158/1078-0432.CCR-08-2740. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509175 Clinical Trial.
-
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426. Oncologist. 2007. PMID: 17470685 Review.
-
Angiogenesis inhibition in solid tumors.Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review.
Cited by
-
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.Eur Radiol. 2012 Jul;22(7):1451-64. doi: 10.1007/s00330-012-2446-x. Epub 2012 May 7. Eur Radiol. 2012. PMID: 22562143
-
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77. doi: 10.1038/nrclinonc.2012.2. Nat Rev Clin Oncol. 2012. PMID: 22330689 Review.
-
Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients.Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2338-2352. doi: 10.1007/s00259-024-06661-6. Epub 2024 Feb 27. Eur J Nucl Med Mol Imaging. 2024. PMID: 38411667
-
The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a006593. doi: 10.1101/cshperspect.a006593. Cold Spring Harb Perspect Med. 2012. PMID: 23209176 Free PMC article. Review.
-
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.Invest New Drugs. 2011 Feb;29(1):137-43. doi: 10.1007/s10637-009-9347-0. Epub 2009 Nov 19. Invest New Drugs. 2011. PMID: 19924384 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous